Perianal crohn’s disease

A review

Anna C. Juncadella, Amer M. Alame, Laurence Sands, Amar R Deshpande

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Perianal involvement in Crohn’s disease (CD), which encompasses fistulas, ulcers, abscesses, strictures and cancer, can lead to significant impairment in quality of life. The objective of this article is to review the major perianal complications of CD and the current medical and surgical modalities used to treat them. Antibiotics are commonly used despite a lack of controlled trials to validate their use and should be used as a bridge to maintenance therapy. The anti-metabolites azathioprine and 6-MP have shown a positive response in terms of fistula closure, although these data are mostly from trials looking at this as a secondary endpoint. Infliximab is an effective agent for induction and maintenance of treatment of fistulizing CD. Further studies to evaluate the use of subcutaneous anti-tumor necrosis factors are needed to convincingly prove their efficacy for perianal fistulizing disease. In CD, clinicians should avoid surgery as a first-line approach for skin tags, hemorrhoids or fissures in the setting of proctitis. Surgery, particularly lateral internal sphincterotomy, in combination with medical therapy is associated with higher fissure healing rates in the absence of proctitis. Fistulotomy is curative for most simple low perianal fistulae, but complex fistulas often require sphincter-sparing surgical procedures. Less invasive approaches such as a chemical sphincterotomy should be used first, with therapy escalated only if this fails.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalPostgraduate Medicine
Volume127
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Crohn Disease
Fistula
Proctitis
Tumor Necrosis Factors
Hemorrhoids
Azathioprine
Abscess
Ulcer
Pathologic Constriction
Therapeutics
Quality of Life
Anti-Bacterial Agents
Skin
Neoplasms

Keywords

  • Crohn’s disease
  • Fistula
  • Management
  • Medical
  • Perianal
  • Surgical

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Perianal crohn’s disease : A review. / Juncadella, Anna C.; Alame, Amer M.; Sands, Laurence; Deshpande, Amar R.

In: Postgraduate Medicine, Vol. 127, No. 3, 01.01.2015, p. 266-272.

Research output: Contribution to journalArticle

Juncadella, Anna C. ; Alame, Amer M. ; Sands, Laurence ; Deshpande, Amar R. / Perianal crohn’s disease : A review. In: Postgraduate Medicine. 2015 ; Vol. 127, No. 3. pp. 266-272.
@article{1799dd90ca7e46d4945518c0ddedb184,
title = "Perianal crohn’s disease: A review",
abstract = "Perianal involvement in Crohn’s disease (CD), which encompasses fistulas, ulcers, abscesses, strictures and cancer, can lead to significant impairment in quality of life. The objective of this article is to review the major perianal complications of CD and the current medical and surgical modalities used to treat them. Antibiotics are commonly used despite a lack of controlled trials to validate their use and should be used as a bridge to maintenance therapy. The anti-metabolites azathioprine and 6-MP have shown a positive response in terms of fistula closure, although these data are mostly from trials looking at this as a secondary endpoint. Infliximab is an effective agent for induction and maintenance of treatment of fistulizing CD. Further studies to evaluate the use of subcutaneous anti-tumor necrosis factors are needed to convincingly prove their efficacy for perianal fistulizing disease. In CD, clinicians should avoid surgery as a first-line approach for skin tags, hemorrhoids or fissures in the setting of proctitis. Surgery, particularly lateral internal sphincterotomy, in combination with medical therapy is associated with higher fissure healing rates in the absence of proctitis. Fistulotomy is curative for most simple low perianal fistulae, but complex fistulas often require sphincter-sparing surgical procedures. Less invasive approaches such as a chemical sphincterotomy should be used first, with therapy escalated only if this fails.",
keywords = "Crohn’s disease, Fistula, Management, Medical, Perianal, Surgical",
author = "Juncadella, {Anna C.} and Alame, {Amer M.} and Laurence Sands and Deshpande, {Amar R}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/00325481.2015.1023160",
language = "English (US)",
volume = "127",
pages = "266--272",
journal = "Postgraduate Medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "3",

}

TY - JOUR

T1 - Perianal crohn’s disease

T2 - A review

AU - Juncadella, Anna C.

AU - Alame, Amer M.

AU - Sands, Laurence

AU - Deshpande, Amar R

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Perianal involvement in Crohn’s disease (CD), which encompasses fistulas, ulcers, abscesses, strictures and cancer, can lead to significant impairment in quality of life. The objective of this article is to review the major perianal complications of CD and the current medical and surgical modalities used to treat them. Antibiotics are commonly used despite a lack of controlled trials to validate their use and should be used as a bridge to maintenance therapy. The anti-metabolites azathioprine and 6-MP have shown a positive response in terms of fistula closure, although these data are mostly from trials looking at this as a secondary endpoint. Infliximab is an effective agent for induction and maintenance of treatment of fistulizing CD. Further studies to evaluate the use of subcutaneous anti-tumor necrosis factors are needed to convincingly prove their efficacy for perianal fistulizing disease. In CD, clinicians should avoid surgery as a first-line approach for skin tags, hemorrhoids or fissures in the setting of proctitis. Surgery, particularly lateral internal sphincterotomy, in combination with medical therapy is associated with higher fissure healing rates in the absence of proctitis. Fistulotomy is curative for most simple low perianal fistulae, but complex fistulas often require sphincter-sparing surgical procedures. Less invasive approaches such as a chemical sphincterotomy should be used first, with therapy escalated only if this fails.

AB - Perianal involvement in Crohn’s disease (CD), which encompasses fistulas, ulcers, abscesses, strictures and cancer, can lead to significant impairment in quality of life. The objective of this article is to review the major perianal complications of CD and the current medical and surgical modalities used to treat them. Antibiotics are commonly used despite a lack of controlled trials to validate their use and should be used as a bridge to maintenance therapy. The anti-metabolites azathioprine and 6-MP have shown a positive response in terms of fistula closure, although these data are mostly from trials looking at this as a secondary endpoint. Infliximab is an effective agent for induction and maintenance of treatment of fistulizing CD. Further studies to evaluate the use of subcutaneous anti-tumor necrosis factors are needed to convincingly prove their efficacy for perianal fistulizing disease. In CD, clinicians should avoid surgery as a first-line approach for skin tags, hemorrhoids or fissures in the setting of proctitis. Surgery, particularly lateral internal sphincterotomy, in combination with medical therapy is associated with higher fissure healing rates in the absence of proctitis. Fistulotomy is curative for most simple low perianal fistulae, but complex fistulas often require sphincter-sparing surgical procedures. Less invasive approaches such as a chemical sphincterotomy should be used first, with therapy escalated only if this fails.

KW - Crohn’s disease

KW - Fistula

KW - Management

KW - Medical

KW - Perianal

KW - Surgical

UR - http://www.scopus.com/inward/record.url?scp=84964030236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964030236&partnerID=8YFLogxK

U2 - 10.1080/00325481.2015.1023160

DO - 10.1080/00325481.2015.1023160

M3 - Article

VL - 127

SP - 266

EP - 272

JO - Postgraduate Medicine

JF - Postgraduate Medicine

SN - 0032-5481

IS - 3

ER -